• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arcturus Therapeutics Holdings Inc. (Amendment)

    2/5/24 6:08:57 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARCT alert in real time by email
    SC 13G/A 1 arct130246sc13ga2.htm AMENDMENT NO. 2

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     ________________ 

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    Arcturus Therapeutics Holdings Inc.
    (Name of Issuer)
     
    Common stock, par value $0.001 per share
    (Title of Class of Securities)
     
    03969T109
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x       Rule 13d-1(b)

     

    o       Rule 13d-1(c)

     

    o       Rule 13d-1(d)

     

     

                                                                 

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 9 
     

     

    CUSIP No. 03969T109 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sumitomo Mitsui Trust Holdings, Inc.  (“SMTH”)

      

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    1,320,652

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    1,320,652

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,320,652

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.94%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, FI

     

     Page 2 of 9 
     

     

    CUSIP No. 03969T109 13G/A  

     

    1.

    NAMES OF REPORTING PERSONS

     

    Nikko Asset Management Co., Ltd. (“NAM”)

        

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
       

    (b) o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

    0

     

    6.

    SHARED VOTING POWER

    1,320,652

     

    7.

    SOLE DISPOSITIVE POWER

    0

     

    8.

    SHARED DISPOSITIVE POWER

    1,320,652

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,320,652

     

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.94%

    12.

    TYPE OF REPORTING PERSON

     

    IA, HC, FI

     

     

     Page 3 of 9 
     

     

    Item 1(a).Name of Issuer:

     

    Arcturus Therapeutics Holdings Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    10628 Science Center Drive, Suite 250 San Diego, California 92121

     

    Item 2(a).Name of Person Filing:

     

    Sumitomo Mitsui Trust Holdings, Inc.

     

    Nikko Asset Management Co., Ltd.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    SMTH: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

     

    NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

     

    Item 2(c).Citizenship:

     

    SMTH: Japan

     

    NAM: Japan

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, par value $0.001 per share

     

    Item 2(e).CUSIP Number:

     

    03969T109

     

     Page 4 of 9 
     

     

    Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    SMTH:

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) o  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

     

    NAM:

     

    (a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
         
    (b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) x  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

     Page 5 of 9 
     

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

     

    SMTH:        
             
    (a)       Amount beneficially owned: 1,320,652
             
    (b)       Percent of class: 4.94%
             
    (c)       Number of shares as to which such person has:
             
      (i)   Sole power to vote or to direct the vote: 0
             
      (ii)   Shared power to vote or to direct the vote: 1,320,652
             
      (iii)   Sole power to dispose or to direct the disposition of: 0
             
      (iv)  

    Shared power to dispose or to direct the disposition of: 1,320,652

             
    NAM:        
             
    (a)       Amount beneficially owned: 1,320,652
             
    (b)       Percent of class: 4.94%
             
    (c)       Number of shares as to which such person has:
             
      (i)   Sole power to vote or to direct the vote: 0
             
      (ii)   Shared power to vote or to direct the vote: 1,320,652
             
      (iii)   Sole power to dispose or to direct the disposition of: 0
             
      (iv)   Shared power to dispose or to direct the disposition of: 1,320,652

     

     Page 6 of 9 
     

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    See Exhibit A.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 9 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 5, 2024

     

      Sumitomo Mitsui Trust Holdings, Inc.
      (Company)
       
      /s/ Hideaki Takamiya
     

    (Signature)

     

    Hideaki Takamiya / Senior Manager of Risk
    Management Dept 

      (Name/Title)
       
      Nikko Asset Management Co.,Ltd 
      (Company)
       
      /s/ Atsushi Ohya
     

    (Signature)

     

    Atsushi Ohya / Head of Business Regulatory Compliance 

      (Name/Title)

     

     Page 8 of 9 
     

     

    Exhibit A

     

    Pursuant to the instructions in Item 7 of Schedule 13G, the securities being reported on by each of SMTH and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

     

    Page 9 of 9

     

     

    Get the next $ARCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARCT

    DatePrice TargetRatingAnalyst
    5/28/2025$32.00Sector Outperform
    Scotiabank
    1/28/2025$41.00Buy
    BTIG Research
    8/12/2024$70.00Outperform
    Leerink Partners
    12/13/2023$90.00Buy
    Canaccord Genuity
    7/24/2023$71.00Outperform
    William Blair
    5/11/2023$19.00 → $51.00Neutral → Buy
    H.C. Wainwright
    11/14/2022$35.00Overweight
    Wells Fargo
    11/10/2022$18.00Neutral → Underperform
    Robert W. Baird
    More analyst ratings

    $ARCT
    SEC Filings

    See more
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      6/6/25 4:05:57 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Arcturus Therapeutics Holdings Inc.

      10-Q - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:11:34 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Arcturus Therapeutics Holdings Inc. (0001768224) (Filer)

      5/12/25 4:05:47 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Farrell Peter C

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/11/25 8:02:07 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Slaoui Moncef

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/11/25 8:01:48 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Marquet Magda

      4 - Arcturus Therapeutics Holdings Inc. (0001768224) (Issuer)

      6/11/25 8:01:31 PM ET
      $ARCT
      Biotechnology: Pharmaceutical Preparations
      Health Care